Panorama Research Incorporated — Department of Health and Human Services SBIR Phase II: R

Description

DESCRIPTION provided by applicant Antibody Membrane Switch AMS technology for optimized antibody engineering Abstract Generation of high productivity cell lines remains a major bottleneck in therapeutic antibody development Conventional cell line development depends on gene amplification methodologies using dihydrofolate reductase DHFR or glutamine synthetase GS Higher productivity is associated with an increased gene copy number However lack of selection pressure under the conditions of large scale manufacturing leads to clonal instability We have developed a novel method for cell line development Antibody Membrane Switch AMS technology that does not rely on gene amplification This FACS based high throughput method is facilitated by cell surface antibody expression to rapidly and efficiently isolate high producing cells The switch between membrane expression and secretion is achieved by alternative splicing and specific DNA recombination The antibody of interest is initially displayed on the cell surface to facilitate FACS Isolated high producing cells are then seamlessly transformed into production cells after removing the membrane anchoring domain sequence via a DNA recombinase AMS technology has been applied in a number of antibody cell line development projects which typically last months The top manufacturing cell lines exhibit very high specific productivity of pg cell day resulting in production titers of g L in day batch culture In Phase I studies the underlying AMS methods were reduce to practice Furthermore we have optimized the AMS process using two biosimilar antibodies In Phase II these optimized methods will be applied to screening of CHO surface displayed antibody libraries An affinity maturation library and a na ve human antibody library will be constructed and utilized to screen by FACS for therapeutic antibody candidates The screening will be carried out with soluble antigen for high affinity binding or antigen e g GPCR presenting cells for desired bio activities The isolated positive cells will be transformed into antibody production cells by DNA recombinase to remove the membrane anchorage This successful application of AMS technology will permit the discovery of antibodies to be seamlessly linked to downstream cell line development providing the basis for rapid facile cell line production directly from a novel antibody discovery platform Phase I R AI A PUBLIC HEALTH RELEVANCE Therapeutic antibodies are expensive in part due to the costly time consuming steps involved in the development of stable high expressing cell lines for production We describe a novel cell line development method that utilizes alternative splicing of a membrane anchored Fc domain and fluorescence activated cell sorting FACS to rapidly identify antibody production cell lines with greatly reduced time and cost The same platform will be optimized to screen affinity maturation or synthetic antibody libraries and thereby facilitating seamless transformation into production cell lines